roxadustat

Phase 3Completed

0 views this week 0 watching⚡ Active

Interest: 40/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

ESA-naive Hemodialysis Chronic Kidney Disease Patients With Anemia

Conditions

ESA-naive Hemodialysis Chronic Kidney Disease Patients With Anemia

Trial Timeline

Jun 2, 2016 → Dec 12, 2017

NCT ID

NCT02780141

About roxadustat

roxadustat is a phase 3 stage product being developed by Astellas Pharma for ESA-naive Hemodialysis Chronic Kidney Disease Patients With Anemia. The current trial status is completed. This product is registered under clinical trial identifier NCT02780141. Target conditions include ESA-naive Hemodialysis Chronic Kidney Disease Patients With Anemia.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (12)

NCT ID	Phase	Status	Start	Completion	Indication
NCT05970172	Phase 3	Recruiting	Jan 16, 2024	Oct 30, 2027	Chronic Kidney Disease
NCT04408820	Pre-clinical	Completed	Jun 1, 2020	Jun 23, 2025	Renal Anemia
NCT04076943	Phase 2	Completed	Aug 20, 2019	Apr 23, 2021	Chemotherapy Induced Anemia
NCT03960489	Phase 1	Completed	Jul 31, 2019	Oct 14, 2019	Healthy Adult Subjects
NCT02964936	Phase 3	Completed	Jan 11, 2017	Aug 15, 2018	Chronic Kidney Disease
NCT02965040	Phase 1	Completed	Dec 12, 2016	Dec 11, 2017	Normal Renal Function
NCT02780726	Phase 3	Completed	Jun 22, 2016	Aug 2, 2017	Peritoneal Dialysis Chronic Kidney Disease Patients With Anemia
NCT02780141	Phase 3	Completed	Jun 2, 2016	Dec 12, 2017	ESA-naive Hemodialysis Chronic Kidney Disease Patients With Anemia
NCT02779764	Phase 3	Completed	May 16, 2016	Nov 28, 2017	Hemodialysis Patients With Renal Anemia
NCT01630889	Phase 2	Completed	May 18, 2012	Dec 12, 2019	Chronic Kidney Disease
NCT01244763	Phase 2	Completed	Oct 29, 2010	Jun 13, 2012	Chronic Kidney Disease
NCT01083888	Phase 1	Completed	Feb 15, 2010	Jun 7, 2010	Anemia